While the routine clinical deployment of MSOT is still uncharted territory, the technology has already proven that it can make an impact in various point-of-care diagnostic applications in humans. A variety of clinical studies have been conducted or are currently ongoing, including such in the fields of melanoma, inflammatory bowel disease (Crohn's disease), breast cancer, thyroid cancer, and peripheral vascular disease.
The unique MSOT ability to visualize intrinsic tissue contrast, blood oxygenation, melanin, lipids and chromophores that are already FDA-approved for clinical use (i.e. ICG, methylene blue), circumvents the major bottleneck of new imaging technologies with the potential to accelerate clinical propagation.
Based on the real-time multispectral imaging technology proven in iThera Medical’s MSOT inSight / inVision small animal imaging systems, an MSOT imaging system for exploratory clinical research, the MSOT Acuity, is now available.
Equipped with a fast-tunable 50 Hz laser and custom-made 2D or 3D detectors the MSOT Acuity can be used for real-time visualization and quantification of disease-related changes in tissue chromophore distribution and concentration.
For more information: play video
The MSOT Acuity has already been used in several investigator initiated trials. iThera Medical invites academic partners to collaborate in the clinical translation of MSOT.
CE mark for clinical use of this product is expected in 2017.
Page layout: 0
Page level: 3
Browser:
Agent